492.50 -22.25 (-4.32%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
491.0
Today’s High
510.2
52 Week Low
507.0
52 Week High
1025.0
492.10 -22.85 (-4.44%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
491
Today’s High
511.7
52 Week Low
501
52 Week High
1014.9
Key Metrics
- Market Cap (In Cr) 2725.61
- Beta 0.53
- Div. Yield (%) 2.91
- P/B 5.17
- TTM P/E 43.8
- Peg Ratio 51.18
- Sector P/E 39.31
- D/E 0.04
- Open Price 500
- Prev Close 514.75
Analysis
Price Analysis
-
1 Week-3.78%
-
3 Months-23.09%
-
6 Month-18.33%
-
YTD-16.76%
-
1 Year-46.56%
Risk Meter
- 36% Low risk
- 36% Moderate risk
- 36% Balanced Risk
- 36% High risk
- 36% Extreme risk
Recos
3 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 0
- Buy
- 0
- Strong Buy
- 3
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 588.86
- Selling/ General/ Admin Expenses Total
- 177.31
- Depreciation/ Amortization
- 33.87
- Other Operating Expenses Total
- 4.17
- Total Operating Expense
- 385.71
- Operating Income
- 203.15
- Net Income Before Taxes
- 227.72
- Net Income
- 176.14
- Diluted Normalized EPS
- 32.93
- Period
- 2022
- Total Assets
- 607.66
- Total Liabilities
- 81.09
- Total Equity
- 526.57
- Tangible Book Valueper Share Common Eq
- 80.42
- Period
- 2022
- Cashfrom Operating Activities
- 113.41
- Cashfrom Investing Activities
- -23.57
- Cashfrom Financing Activities
- -89.41
- Net Changein Cash
- 0.43
- Period
- 2021
- Total Revenue
- 494.62
- Selling/ General/ Admin Expenses Total
- 155.61
- Depreciation/ Amortization
- 30.28
- Other Operating Expenses Total
- 2.51
- Total Operating Expense
- 351.86
- Operating Income
- 142.76
- Net Income Before Taxes
- 152.47
- Net Income
- 113.15
- Diluted Normalized EPS
- 20.55
- Period
- 2021
- Total Assets
- 545.8
- Total Liabilities
- 118.52
- Total Equity
- 427.28
- Tangible Book Valueper Share Common Eq
- 61.66
- Period
- 2021
- Cashfrom Operating Activities
- 116.04
- Cashfrom Investing Activities
- -50.23
- Cashfrom Financing Activities
- -61.57
- Net Changein Cash
- 4.24
- Period
- 2020
- Total Revenue
- 433.2
- Selling/ General/ Admin Expenses Total
- 138.6
- Depreciation/ Amortization
- 31.91
- Other Operating Expenses Total
- 3.52
- Total Operating Expense
- 299.17
- Operating Income
- 134.03
- Net Income Before Taxes
- 140.42
- Net Income
- 88.41
- Diluted Normalized EPS
- 17.49
- Period
- 2020
- Total Assets
- 469.33
- Total Liabilities
- 102.67
- Total Equity
- 366.66
- Tangible Book Valueper Share Common Eq
- 50.2
- Period
- 2020
- Cashfrom Operating Activities
- 167.63
- Cashfrom Investing Activities
- 0.95
- Cashfrom Financing Activities
- -164.78
- Net Changein Cash
- 3.8
- Period
- 2019
- Total Revenue
- 402.91
- Selling/ General/ Admin Expenses Total
- 135.99
- Depreciation/ Amortization
- 26.17
- Other Operating Expenses Total
- 2.13
- Total Operating Expense
- 274.82
- Operating Income
- 128.09
- Net Income Before Taxes
- 138.06
- Net Income
- 85.14
- Diluted Normalized EPS
- 15.79
- Period
- 2019
- Total Assets
- 474.72
- Total Liabilities
- 39.6
- Total Equity
- 435.12
- Tangible Book Valueper Share Common Eq
- 61.86
- Period
- 2019
- Cashfrom Operating Activities
- 100.31
- Cashfrom Investing Activities
- -11.59
- Cashfrom Financing Activities
- -93.63
- Net Changein Cash
- -4.91
- Period
- 2018
- Total Revenue
- 356.32
- Selling/ General/ Admin Expenses Total
- 114.5
- Depreciation/ Amortization
- 20.1
- Other Operating Expenses Total
- 1.41
- Total Operating Expense
- 225.29
- Operating Income
- 131.02
- Net Income Before Taxes
- 144.99
- Net Income
- 93.28
- Diluted Normalized EPS
- 16.64
- Period
- 2018
- Total Assets
- 478.99
- Total Liabilities
- 35.7
- Total Equity
- 443.29
- Tangible Book Valueper Share Common Eq
- 62.31
- Period
- 2018
- Cashfrom Operating Activities
- 107.03
- Cashfrom Investing Activities
- -43.22
- Cashfrom Financing Activities
- -63.88
- Net Changein Cash
- -0.06
- Period
- 2017
- Total Revenue
- 304.39
- Selling/ General/ Admin Expenses Total
- 105.81
- Depreciation/ Amortization
- 18.05
- Other Operating Expenses Total
- 1.78
- Total Operating Expense
- 234.5
- Operating Income
- 69.88
- Net Income Before Taxes
- 81.67
- Net Income
- 42.84
- Diluted Normalized EPS
- 10.66
- Period
- 2017
- Total Assets
- 437.83
- Total Liabilities
- 30.02
- Total Equity
- 407.81
- Tangible Book Valueper Share Common Eq
- 55.9
- Period
- 2017
- Cashfrom Operating Activities
- 89.57
- Cashfrom Investing Activities
- -41.52
- Cashfrom Financing Activities
- -48.52
- Net Changein Cash
- -0.46
- Period
- 2022-09-30
- Total Revenue
- 134.97
- Selling/ General/ Admin Expenses Total
- 29.17
- Depreciation/ Amortization
- 9.15
- Other Operating Expenses Total
- 33.1
- Total Operating Expense
- 112.54
- Operating Income
- 22.43
- Net Income Before Taxes
- 23.61
- Net Income
- 15.43
- Diluted Normalized EPS
- 3.8
- Period
- 2022-09-30
- Total Assets
- 570.69
- Total Liabilities
- 78.07
- Total Equity
- 492.62
- Tangible Book Valueper Share Common Eq
- 73.94
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 56.93
- Cashfrom Investing Activities
- 32.89
- Cashfrom Financing Activities
- -83.18
- Net Changein Cash
- 6.64
- Period
- 2022-06-30
- Total Revenue
- 127.79
- Selling/ General/ Admin Expenses Total
- 21.65
- Depreciation/ Amortization
- 8.61
- Other Operating Expenses Total
- 30.72
- Total Operating Expense
- 100.48
- Operating Income
- 27.31
- Net Income Before Taxes
- 28.01
- Net Income
- 21.73
- Diluted Normalized EPS
- 4.1
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 130.56
- Selling/ General/ Admin Expenses Total
- 17.43
- Depreciation/ Amortization
- 9.67
- Other Operating Expenses Total
- 33.65
- Total Operating Expense
- 102.64
- Operating Income
- 27.92
- Net Income Before Taxes
- 30.02
- Net Income
- 21.24
- Diluted Normalized EPS
- 4.02
- Period
- 2022-03-31
- Total Assets
- 607.66
- Total Liabilities
- 81.09
- Total Equity
- 526.57
- Tangible Book Valueper Share Common Eq
- 80.42
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 113.41
- Cashfrom Investing Activities
- -23.57
- Cashfrom Financing Activities
- -89.41
- Net Changein Cash
- 0.43
- Period
- 2021-12-31
- Total Revenue
- 117.4
- Selling/ General/ Admin Expenses Total
- 14.7
- Depreciation/ Amortization
- 8.8
- Other Operating Expenses Total
- 35.9
- Total Operating Expense
- 89.4
- Operating Income
- 28
- Net Income Before Taxes
- 28.7
- Net Income
- 21.5
- Diluted Normalized EPS
- 4.05
- Period
- 2021-12-31
- Total Assets
- 595.6
- Total Liabilities
- 91.2
- Total Equity
- 504.4
- Tangible Book Valueper Share Common Eq
- 76.22
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 176.21
- Selling/ General/ Admin Expenses Total
- 15.02
- Depreciation/ Amortization
- 8.16
- Other Operating Expenses Total
- 28.29
- Total Operating Expense
- 95.08
- Operating Income
- 81.13
- Net Income Before Taxes
- 95.44
- Net Income
- 77.73
- Diluted Normalized EPS
- 14.67
- Period
- 2021-09-30
- Total Assets
- 583.49
- Total Liabilities
- 101.07
- Total Equity
- 482.42
- Tangible Book Valueper Share Common Eq
- 72.07
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 70.24
- Cashfrom Investing Activities
- 7.1
- Cashfrom Financing Activities
- -84.43
- Net Changein Cash
- -7.09
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day530.28
- 10 Day540.15
- 20 Day554.99
- 50 Day596.42
- 100 Day631.29
- 300 Day654.22
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Vijaya Diagnostic Centre
- 431.95
- 10
- 2.37
- 527.45
- 292
- 4310.89
- Healthcare Global Enterprises
- 278.5
- -5.55
- -1.95
- 320
- 221.05
- 3937.72
- Thyrocare Technologies
- 492.5
- -22.25
- -4.32
- 1025
- 507
- 2725.61
- Kovai Medical Centre & Hospital
- 1773
- 34.1
- 1.96
- 1924.95
- 1309.02
- 1889.51
- Shalby
- 141.55
- 1.7
- 1.22
- 167.95
- 95.1
- 1501.12
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Vijaya Diagnostic Centre
- 39.66
- 9.2
- -
- -
- Healthcare Global Enterprises
- -
- 4.52
- -9.21
- -6.06
- Thyrocare Technologies
- 15.64
- 5.17
- 25.99
- 24.43
- Kovai Medical Centre & Hospital
- 18
- 3.1
- 19.01
- 10.75
- Shalby
- 26.34
- 1.73
- 5.23
- 7.93
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 28.86%
- 15,273,587
- Arisaig Asia Fund Limited
- 6.11%
- 3,231,412
- Theleme India Master Fund Limited
- 1.2%
- 632,920
- Others
- 2.82%
- 1,499,868
- Others
- 7.48%
- 3,960,659
- Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund
- 6.38%
- 3,378,299
- Others
- 0.91%
- 484,847
- Others
- 1.08%
- 572,565
- Others
- 0.99%
- 522,008
- Others
- 0.59%
- 310,883
- Others
- 0.58%
- 309,544
- HUF
- 0.19%
- 102,657
- Clearing Members
- 0.09%
- 45,267
- LLP
- 0.06%
- 30,900
- Trusts
- 0%
- 343
- Others
- 0.3%
- 159,967
- Others
- 0.06%
- 29,879
- Others
- 0%
- 1,394
- Others
- 0%
- 175
- Non Promoter - Non Public shareholder
- 0%
- 364
- Others
- 0%
- 364
- Promoter & Promoter Group Shareholding
- 71.14%
- 37,656,092
- Docon Technologies Private Limited
- 71.14%
- 37,656,092
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 03-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 01-Aug-22
- Quarterly Results
- 29-Apr-22
- Audited Results & Dividend
- 12-Feb-22
- Quarterly Results
- 13-Nov-21
- Quarterly Results
- 12-Aug-21
- Quarterly Results
- 08-May-21
- Audited Results & Final Dividend
- 30-Jan-21
- Quarterly Results & 2nd Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 26-Jun-21
- 07-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-May-22
- 12-May-22
- 11-May-22
- 15
- 10-May-21
- -
- 17-Jun-21
- 15
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Thyrocare Technologies
- Industry Healthcare Facilities
- ISIN INE594H01019
- BSE Code 539871
- NSE Code THYROCARE
Thyrocare Technologies Limited is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. It also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
MANAGEMENT
- Rahul Guha Chief Executive Officer, Managing Director
- Sachin Salvi Chief Financial Officer
- Kallathikumar K Chief Operating Officer
- Ramjee Dorai Chief Compliance Officer, Company Secretary
- Aditya Shinde Vice President - Finance
- Caesar Sengupta Vice President - Operations
- M. Chandrasekhar Vice President - Infrastructure
- Dharmil Sheth Managing Director, Non-Executive Non-Independent Director
- S. Krishnakumar General Manager - Laboratory
- Santhosh Manickam General Manager
Company Summary
THYROCARE TECHNOLOGIES SUMMARY
Thyrocare Technologies is trading 4.32% lower at Rs 492.50 as compared to its last closing price. Thyrocare Technologies has been trading in the price range of 510.2 & 491.0. Thyrocare Technologies has given -16.76% in this year & -3.78% in the last 5 days.
Thyrocare Technologies has TTM P/E ratio 43.8 as compared to the sector P/E of 39.31. There are 3 analysts who have initiated coverage on Thyrocare Technologies. There are 3 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 15.43 Crores in its last quarter.
Listed peers of Thyrocare Technologies include Vijaya Diagnostic Centre (2.37%), Healthcare Global Enterprises (-1.95%), Thyrocare Technologies (-4.32%) etc.
Thyrocare Technologies has a 71.14% promoter holding & 0% public holding.
FAQs about Thyrocare Technologies
Thyrocare Technologies is trading at 492.50 as on 6 Feb, 2023 3:49:15 PM. This is -4.32% lower as compared to its previous closing price of 514.75
The market capitalization of Thyrocare Technologies is 2725.61 Cr as on 6 Feb, 2023 3:49:15 PM.
The average broker rating on Thyrocare Technologies is Strong Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 0 analysts have given a hold rating
- 0 analysts have given a buy rating
- 3 analysts have given a strong buy rating
The 52 wk high for Thyrocare Technologies is 1025.0 whereas the 52 wk low is 507.0
Thyrocare Technologies can be analyzed on the following key metrics -
- TTM P/E: 43.8
- Sector P/E: 39.31
- Dividend Yield: 2.91%
- D/E ratio: -
Thyrocare Technologies reported a net profit of 176.14 Cr in 2022.
